Neurology, Yale University, New Haven, CT (A.d.H., A.B., M.A.).
Neurology, Mercy Health, Toledo, OH (O.O.Z.).
Stroke. 2023 Jun;54(6):1695-1705. doi: 10.1161/STROKEAHA.122.040008. Epub 2023 Mar 20.
Large vessel occlusion stroke due to underlying intracranial atherosclerotic disease (ICAD-LVO) is prevalent in 10 to 30% of LVOs depending on patient factors such as vascular risk factors, race and ethnicity, and age. Patients with ICAD-LVO derive similar functional outcome benefit from endovascular thrombectomy as other mechanisms of LVO, but up to half of ICAD-LVO patients reocclude after revascularization. Therefore, early identification and treatment planning for ICAD-LVO are important given the unique considerations before, during, and after endovascular thrombectomy. In this review of ICAD-LVO, we propose a multistep approach to ICAD-LVO identification, pretreatment and endovascular thrombectomy considerations, adjunctive medications, and medical management. There have been no large-scale randomized controlled trials dedicated to studying ICAD-LVO, therefore this review focuses on observational studies.
由于颅内动脉粥样硬化性疾病(ICAD-LVO)导致的大血管闭塞性卒中(LVO)在 10%至 30%的 LVO 患者中较为常见,具体取决于患者的血管危险因素、种族和民族以及年龄等因素。ICAD-LVO 患者从血管内血栓切除术获得的功能结局获益与其他 LVO 机制相似,但多达一半的 ICAD-LVO 患者在再通后再次闭塞。因此,鉴于血管内血栓切除术之前、期间和之后的独特考虑因素,早期识别和治疗 ICAD-LVO 非常重要。在对 ICAD-LVO 的这一综述中,我们提出了一种多步骤方法来识别 ICAD-LVO、治疗前和血管内血栓切除术的考虑因素、辅助药物和医学管理。目前还没有专门针对 ICAD-LVO 进行的大规模随机对照试验,因此本综述重点关注观察性研究。